<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01984216</url>
  </required_header>
  <id_info>
    <org_study_id>CIRUGIA-CHN</org_study_id>
    <secondary_id>2013-000693-30</secondary_id>
    <nct_id>NCT01984216</nct_id>
  </id_info>
  <brief_title>Billroth II Versus Roux-en-Y for the Gastrojejunostomy in the Pancreatoduodenectomy</brief_title>
  <official_title>Billroth II Versus Roux-en-Y for the Gastrojejunostomy Reconstruction in the Pancreatoduodenectomy: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Miguel Servet</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and superiority of Roux-Y versus Billroth
      II gastrojejunostomy reconstruction on delayed gastric emptying after pancreatoduodenectomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Incidence of delayed gastric emptying (DGE)</measure>
    <time_frame>30 day after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Pancreatoduodenectomy</condition>
  <arm_group>
    <arm_group_label>Roux-en-Y</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roux-en-Y for the gastrojejunostomy reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Billroth II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Billroth II for the gastrojejunostomy reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y for the gastrojejunostomy reconstruction</intervention_name>
    <arm_group_label>Roux-en-Y</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Billroth II for the gastrojejunostomy reconstruction</intervention_name>
    <arm_group_label>Billroth II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive series of patients undergoing pancreaticoduodenectomy (PD).

          -  Given informed consent.

        Exclusion Criteria:

          -  Inability to perform pancreatogastrostomy.

          -  Resection of other organs, except the superior mesenteric-portal vein.

          -  Previous gastric surgery.

          -  Preoperative gastric or duodenal obstruction.

          -  Previous complex abdominal surgery.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Javier Herrera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Javier Herrera, MD</last_name>
    <phone>00 34 848422187</phone>
    <email>javier.herrera.cabezon@cfnavarra.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cruz Zazpe, MD</last_name>
    <phone>00 34 848422187</phone>
    <email>cruz.zazpe.ripa@cfnavarra.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarre</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herrera</last_name>
    </contact>
    <contact_backup>
      <last_name>Ferran Capdevila, PharmD</last_name>
      <phone>00 34 848422163</phone>
      <email>fcapdevb@navarra.es</email>
    </contact_backup>
    <investigator>
      <last_name>Francisco Javier Herrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cruz Zazpe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Miguel Lera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Luis Viudez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Sanchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.navarrabiomed.es</url>
    <description>Navarrabiomed: the biomedical research branch of Complejo Hospitalario de Navarra</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
